Yahoo Web Search

Search results

1. www.ucb.com › our-companyOur Company | UCB

   www.ucb.com › our-company

   • Cached

   A global biopharma company, inspired by the needs of people living with severe diseases. At UCB, we are consistently delivering on our commitment to improve the lives of people living with severe neurological and immunological conditions.

   • Management

     Joined UCB in June 2011 Appointed as CEO in January 2015....

   • Partnering

     Partnering with UCB will help you complete the journey and...

   • Health of The Planet

     UCB environmental sustainability program We have made strong...

   • Our Products

     IMPORTANT NOTE. For patients: if you wish to report an...

   • Disease Areas

     For many years, UCB has responded to changing needs for...

   • Pipeline

     Dapirolizumab pegol is an investigational humanised...

2. en.wikipedia.org › wiki › UCB_(company)UCB (company) - Wikipedia

   en.wikipedia.org › wiki › UCB_(company)

   • Cached

   UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease.

   • Founded: 1928
   • Revenue: € 5.777 billion (2021)

   • Number of employees: 7,600 (2020)
   • Headquarters: Brussels, Belgium

3. www.linkedin.com › company › ucb-pharmaUCB | LinkedIn

   www.linkedin.com › company › ucb-pharma

   UCB – The Facts With approximately 9000 employees in around 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in...

4. People also ask

   What makes UCB a world-preferred biopharma company?

   • Now Ninety years later, UCB leads as a global patient-preferred biopharma company with 3.5 million patients using our medicines. We are continuously working to discover novel mechanisms of action and innovative solutions in order to transform the lives of people living with severe diseases.

   UCB’s 90+ Year History – Then, Now, and In the Future | UCB

   www.ucb-usa.com/stories-media/UCB-U-S-News/detail/article/ucbs-90-year-history-then-now-and-future

   See all results for this question

   When did UCB become a biopharma company?

   • In the early years of the 21st century, UCB began to transform into a pure biopharma company. Significant milestones included the acquisition of Celltech, a British biotech firm in 2004, and then German pharma company, Schwarz Pharma, in 2006. A significant breakthrough came in the 1980s when UCB registered Zyrtec© - a novel antihistamine product.

   Our Company | UCB

   www.ucb.com/our-company/about-us

   See all results for this question

   What does UCB stand for?

   • UCB ( Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease.

   UCB (company) - Wikipedia

   en.wikipedia.org/wiki/UCB_(company)

   See all results for this question

   Will UCB acquire Ra Pharma?

   • Brussels (Belgium) and Cambridge, Mass U.S. 10 October 2019 – 7:00 (CEST) - regulated information – inside information – UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) announced today their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma.

   UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve

   www.ucb.com/stories-media/Press-Releases/article/UCB-agrees-to-acquire-Ra-Pharmaceuticals-Joining-forces-to-improve-treatment-options-for-people-living-with-myasthenia-gravis-and-other-rare-diseases

   See all results for this question

5. www.ucb.com › stories-media › Press-ReleasesUCB announces U.S. FDA approval of ZILBRYSQ[®] (zilucoplan ...

   www.ucb.com › stories-media › Press-Releases

   • Cached

   Oct 17, 2023 · 154 Likes. FDA approval of ZILBRYSQ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive1 Zilucoplan is the first once-daily subcutaneous, targeted C5 complement inhibitor for gMG.

6. www.ucb.com › stories-media › Press-ReleasesUCB agrees to acquire Ra Pharmaceuticals: Joining forces to ...

   www.ucb.com › stories-media › Press-Releases

   • Cached

   UCB will develop and, if approved, launch zilucoplan worldwide, accelerating and diversifying company growth · Will accelerate UCB’s long-term innovation capabilities through the addition of Ra Pharmaceuticals ExtremeDiversity™ technology platform · Plan to maintain productive and innovative Ra Pharma unit in Cambridge, MA, to complement ...

7. www.fiercepharma.com › pharma › seeking-blockbusterAfter busy 2023, UCB expects approval spree to keep rolling ...

   www.fiercepharma.com › pharma › seeking-blockbuster

   • Cached

   Feb 28, 2024 · Pharma. Seeking blockbuster status, UCB eyes 4 new indications for psoriasis med Bimzelx in 2024. By Zoey Becker Feb 28, 2024 11:02am. UCB Rystiggo psoriasis. Belgium-based UCB saw three...

8. www.ucb-usa.com › stories-media › UCB-U-S-NewsUCB’s 90+ Year History – Then, Now, and In the Future | UCB

   www.ucb-usa.com › stories-media › UCB-U-S-News

   • Cached

   Now Ninety years later, UCB leads as a global patient-preferred biopharma company with 3.5 million patients using our medicines. We are continuously working to discover novel mechanisms of action and innovative solutions in order to transform the lives of people living with severe diseases.